MAP2K7 and melanoma: Among the 19 patients treated with icatolimab in the dose-expansion part of the NCT04137900 study, one melanoma patient that had previously progressed on nivolumab and BRAF/MEK inhibitors reached a PR with no grade 4/5 TRAEs [225].